Skip to content
value.today

Solid Biosciences Inc.: peers

Change the peers

Solid Biosciences Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Solid Biosciences Inc., Collegium Pharmaceutical, Inc., Ironwood Pharmaceuticals, Inc., Aquestive Therapeutics, Inc., Evolus, Inc., Alpha Teknova, Inc., Harrow Health, Amphastar Pharmaceuticals, Inc. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureSolid Biosciences Inc.base
SLDB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Collegium Pharmaceutical, Inc.
COLL · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Ironwood Pharmaceuticals, Inc.
IRWD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Aquestive Therapeutics, Inc.
AQST · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Evolus, Inc.
EOLS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Alpha Teknova, Inc.
TKNO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Harrow Health
HROW · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Amphastar Pharmaceuticals, Inc.
AMPH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$713 MOct 30, 2026 · Market data4th of 8$715 MOct 28, 2026 · Market data3rd of 8$599 MOct 30, 2026 · Market data5th of 8$508 MOct 30, 2026 · Market data6th of 8$501 MOct 16, 2026 · Market data7th of 8$494 MOct 29, 2026 · Market data8th of 8$1.1 BOct 28, 2026 · Market data1st of 8$1.1 BOct 28, 2026 · Market data2nd of 8$656 M8 ranked
Revenue (Better neither way: ranked highest first)——$781 MFY2025 · SEC1st of 7$296 MFY2025 · SEC4th of 7$45 MFY2025 · SEC6th of 7$297 MFY2025 · SEC3rd of 7$41 MFY2025 · SEC7th of 7$272 MFY2025 · SEC5th of 7$720 MFY2025 · SEC2nd of 7$296 M7 ranked
Net income (Higher is better)$-174 MFY2025 · SEC8th of 8$63 MFY2025 · SEC2nd of 8$24 MFY2025 · SEC3rd of 8$-84 MFY2025 · SEC7th of 8$-52 MFY2025 · SEC6th of 8$-17 MFY2025 · SEC5th of 8$-5 MFY2025 · SEC4th of 8$98 MFY2025 · SEC1st of 8$-11 M8 ranked
Employees (Better neither way: ranked highest first)——234As on December 2020 · Profile3rd of 6219As on 2021 · Profile4th of 6147December 31, 2025 · Profile6th of 6334December 31, 2025 · Profile2nd of 6158December 31, 2025 · Profile5th of 6——1,761As on 2021 · Profile1st of 62276 ranked
Growth
Revenue growth (Higher is better)————+23.6%FY2025 · SEC2nd of 773rd82nd-15.7%FY2025 · SEC6th of 712th7th-22.6%FY2025 · SEC7th of 710th5th+11.6%FY2025 · SEC3rd of 753rd65th+7.4%FY2025 · SEC4th of 743rd53rd+36.4%FY2025 · SEC1st of 780th88th-1.6%FY2025 · SEC5th of 722nd25th+7.4%7 ranked
Revenue growth, 3 years a year (Higher is better)————+18.9%FY2025 · SEC3rd of 771st84th-10.3%FY2025 · SEC7th of 712th10th-2.3%FY2025 · SEC6th of 721st25th+26.0%FY2025 · SEC2nd of 778th89th-0.7%FY2025 · SEC5th of 725th30th+45.4%FY2025 · SEC1st of 787th95th+13.0%FY2025 · SEC4th of 761st76th+13.0%7 ranked
Earnings per share growth (Higher is better)————-7.0%FY2025 · SEC1st of 230th31st————————————————————-33.7%FY2025 · SEC2nd of 215th15th-20.3%2 ranked
Margins and returns
Gross margin (Higher is better)————59.4%FY2025 · SEC3rd of 652nd73rd————58.3%FY2025 · SEC4th of 650th72nd66.3%FY2025 · SEC2nd of 662nd79th33.2%FY2025 · SEC6th of 619th40th75.0%FY2025 · SEC1st of 675th87th49.5%FY2025 · SEC5th of 635th63rd58.8%6 ranked
Operating margin (Higher is better)————23.0%FY2025 · SEC2nd of 791st89th33.3%FY2025 · SEC1st of 796th95th-159.5%FY2025 · SEC7th of 717th7th-11.0%FY2025 · SEC5th of 747th26th-41.9%FY2025 · SEC6th of 734th16th11.2%FY2025 · SEC4th of 775th71st19.5%FY2025 · SEC3rd of 788th85th11.2%7 ranked
Net margin (Higher is better)————8.1%FY2025 · SEC3rd of 775th70th8.1%FY2025 · SEC2nd of 775th70th-188.1%FY2025 · SEC7th of 716th6th-17.4%FY2025 · SEC5th of 744th23rd-42.6%FY2025 · SEC6th of 732nd16th-1.9%FY2025 · SEC4th of 757th39th13.6%FY2025 · SEC1st of 784th82nd-1.9%7 ranked
Free cash flow margin (Higher is better)————42.0%FY2025 · SEC2nd of 798th98th42.9%FY2025 · SEC1st of 798th99th-119.0%FY2025 · SEC7th of 719th7th-15.4%FY2025 · SEC5th of 739th18th-24.2%FY2025 · SEC6th of 735th16th15.8%FY2025 · SEC4th of 782nd82nd16.8%FY2025 · SEC3rd of 783rd83rd15.8%7 ranked
Return on equity (Higher is better)-109.9%FY2025 · SEC5th of 522nd10th23.7%FY2025 · SEC1st of 593rd88th————————————-22.8%FY2025 · SEC4th of 559th27th-8.4%FY2025 · SEC3rd of 567th34th12.9%FY2025 · SEC2nd of 585th73rd-8.4%5 ranked
Return on invested capital (Higher is better)————————————————————————————9.2%FY2025 · SEConly one with it37th42nd9.2%—
Valuation
P/E ratio (Better neither way: ranked highest first)————18.7×price Oct 28, 2026 · Market data1st of 329th49th4.0×price Oct 30, 2026 · Market data3rd of 35th3rd————————————————11.0×price Oct 28, 2026 · Market data2nd of 314th21st11.0×3 ranked
Price to sales (Better neither way: ranked highest first)————0.9×price Oct 28, 2026 · Market data7th of 715th26th1.5×price Oct 30, 2026 · Market data5th of 724th40th10.4×price Oct 30, 2026 · Market data2nd of 774th89th1.5×price Oct 16, 2026 · Market data4th of 725th40th10.8×price Oct 29, 2026 · Market data1st of 775th90th3.6×price Oct 28, 2026 · Market data3rd of 749th68th1.5×price Oct 28, 2026 · Market data6th of 723rd39th1.5×7 ranked
Price to book (Better neither way: ranked highest first)4.0×price Oct 30, 2026 · Market data3rd of 560th70th2.4×price Oct 28, 2026 · Market data4th of 542nd53rd————————————7.2×price Oct 29, 2026 · Market data2nd of 577th84th20.8×price Oct 28, 2026 · Market data1st of 592nd96th1.4×price Oct 28, 2026 · Market data5th of 526th33rd4.0×5 ranked
Free cash flow yield (Higher is better)-22.1%price Oct 30, 2026 · Market data8th of 831st14th45.8%price Oct 28, 2026 · Market data1st of 899th99th21.2%price Oct 30, 2026 · Market data2nd of 898th96th-10.4%price Oct 30, 2026 · Market data7th of 842nd20th-9.1%price Oct 16, 2026 · Market data6th of 844th22nd-2.0%price Oct 29, 2026 · Market data5th of 862nd32nd3.9%price Oct 28, 2026 · Market data4th of 883rd59th11.1%price Oct 28, 2026 · Market data3rd of 895th89th1.0%8 ranked
Financial strength
Debt to equity (Lower is better)————————————————————0.2×FY2025 · SEC1st of 331st22nd4.8×FY2025 · SEC3rd of 394th94th0.8×FY2025 · SEC2nd of 369th60th0.8×3 ranked
Net debt to EBITDA (Lower is better)————————————————————————5.5×FY2025 · SEConly one with it86th84th————5.5×—
Piotroski F-score (Higher is better)——————2 of 9FY2025 · SEC4th of 52 of 9FY2025 · SEC4th of 55 of 9FY2025 · SEC3rd of 56 of 9FY2025 · SEC1st of 56 of 9FY2025 · SEC1st of 55.0 of 95 ranked
Scorecard
Scorecard (Higher is better)1 of 12FY2025 · Scorecard8th of 820 of 23FY2025 · Scorecard1st of 811 of 20FY2025 · Scorecard3rd of 82 of 20FY2025 · Scorecard7th of 88 of 19FY2025 · Scorecard4th of 86 of 21FY2025 · Scorecard6th of 89 of 23FY2025 · Scorecard5th of 820 of 25FY2025 · Scorecard2nd of 841% passed8 ranked
Valuation checks (Higher is better)0 of 4FY2025 · Scorecard6th of 86 of 6FY2025 · Scorecard1st of 85 of 6FY2025 · Scorecard3rd of 80 of 5FY2025 · Scorecard6th of 81 of 5FY2025 · Scorecard4th of 80 of 5FY2025 · Scorecard6th of 81 of 6FY2025 · Scorecard5th of 86 of 6FY2025 · Scorecard1st of 818% passed8 ranked
Growth checks (Higher is better)0 of 2FY2025 · Scorecard7th of 85 of 6FY2025 · Scorecard1st of 81 of 6FY2025 · Scorecard6th of 80 of 6FY2025 · Scorecard7th of 85 of 6FY2025 · Scorecard1st of 82 of 6FY2025 · Scorecard5th of 84 of 6FY2025 · Scorecard3rd of 84 of 6FY2025 · Scorecard3rd of 850% passed8 ranked
Profitability checks (Higher is better)0 of 3FY2025 · Scorecard7th of 84 of 5FY2025 · Scorecard1st of 82 of 4FY2025 · Scorecard2nd of 80 of 4FY2025 · Scorecard7th of 81 of 4FY2025 · Scorecard5th of 81 of 5FY2025 · Scorecard6th of 82 of 5FY2025 · Scorecard4th of 83 of 6FY2025 · Scorecard2nd of 833% passed8 ranked
Financial health checks (Higher is better)1 of 2FY2025 · Scorecard5th of 82 of 3FY2025 · Scorecard3rd of 82 of 3FY2025 · Scorecard3rd of 82 of 4FY2025 · Scorecard5th of 81 of 3FY2025 · Scorecard8th of 83 of 4FY2025 · Scorecard2nd of 82 of 5FY2025 · Scorecard7th of 84 of 4FY2025 · Scorecard1st of 858% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard4th of 83 of 3FY2025 · Scorecard1st of 81 of 1FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard4th of 80 of 1FY2025 · Scorecard4th of 80 of 1FY2025 · Scorecard4th of 80 of 1FY2025 · Scorecard4th of 83 of 3FY2025 · Scorecard1st of 80% passed8 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)106.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8118.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 892.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 860.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 876.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 816.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 860.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 868.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 872.5%8 ranked
Institutions holding (Better neither way: ranked highest first)1582026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 82402026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 82322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 81902026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 81702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 81102026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 82082026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 82272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 81998 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+5.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 8+5.0 pp2026-Q2 against 2026-Q1 · 13F3rd of 8-0.2 pp2026-Q2 against 2026-Q1 · 13F6th of 8-1.4 pp2026-Q2 against 2026-Q1 · 13F7th of 8+14.6 pp2026-Q2 against 2026-Q1 · 13F1st of 8+2.7 pp2026-Q2 against 2026-Q1 · 13F4th of 8-0.1 pp2026-Q2 against 2026-Q1 · 13F5th of 8-6.2 pp2026-Q2 against 2026-Q1 · 13F8th of 8+1.3 pp8 ranked
Dividends
Shareholder yield (Higher is better)————3.5%FY2025 · SEC2nd of 263rd54th————————————————————6.9%FY2025 · SEC1st of 284th79th5.2%2 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Solid Biosciences Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Collegium Pharmaceutical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Ironwood Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Aquestive Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Evolus, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alpha Teknova, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Harrow Health: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Amphastar Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Solid Biosciences Inc.———
Collegium Pharmaceutical, Inc.23.0%FY2025
91st percentile in Healthcaremedian -7.7%, 674 companies
89th percentile in USAmedian 3.5%, 2,594 companies
Ironwood Pharmaceuticals, Inc.33.3%FY2025
96th percentile in Healthcaremedian -7.7%, 674 companies
95th percentile in USAmedian 3.5%, 2,594 companies
Aquestive Therapeutics, Inc.-159.5%FY2025
17th percentile in Healthcaremedian -7.7%, 674 companies
7th percentile in USAmedian 3.5%, 2,594 companies
Evolus, Inc.-11.0%FY2025
47th percentile in Healthcaremedian -7.7%, 674 companies
26th percentile in USAmedian 3.5%, 2,594 companies
Alpha Teknova, Inc.-41.9%FY2025
34th percentile in Healthcaremedian -7.7%, 674 companies
16th percentile in USAmedian 3.5%, 2,594 companies
Harrow Health11.2%FY2025
75th percentile in Healthcaremedian -7.7%, 674 companies
71st percentile in USAmedian 3.5%, 2,594 companies
Amphastar Pharmaceuticals, Inc.19.5%FY2025
88th percentile in Healthcaremedian -7.7%, 674 companies
85th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$195 M$390 M$585 M$781 M20102012201420162018202020222024Solid Biosciences Inc. $8 MCollegium Pharmaceutical, Inc. $781 MIronwood Pharmaceuticals, Inc. $296 MAquestive Therapeutics, Inc. $45 MEvolus, Inc. $297 MAlpha Teknova, Inc. $41 MHarrow Health $272 MAmphastar Pharmaceuticals, Inc. $720 M

Rank in the group

1st2nd3rd4th5th6th7th8th20122013201420152016201720182019202020212022202320242025Solid Biosciences Inc.: 8th of 8 in 2021Solid Biosciences Inc.: 8th of 8 in 2022Solid Biosciences Inc.Collegium Pharmaceutical, Inc.: 4th of 4 in 2016Collegium Pharmaceutical, Inc.: 4th of 5 in 2017Collegium Pharmaceutical, Inc.: 3rd of 5 in 2018Collegium Pharmaceutical, Inc.: 3rd of 6 in 2019Collegium Pharmaceutical, Inc.: 3rd of 7 in 2020Collegium Pharmaceutical, Inc.: 3rd of 8 in 2021Collegium Pharmaceutical, Inc.: 2nd of 8 in 2022Collegium Pharmaceutical, Inc.: 2nd of 7 in 2023Collegium Pharmaceutical, Inc.: 2nd of 7 in 2024Collegium Pharmaceutical, Inc.: 1st of 7 in 2025Collegium Pharmaceutical, Ironwood Pharmaceuticals, Inc.: 2nd of 2 in 2012Ironwood Pharmaceuticals, Inc.: 2nd of 3 in 2013Ironwood Pharmaceuticals, Inc.: 2nd of 3 in 2014Ironwood Pharmaceuticals, Inc.: 2nd of 3 in 2015Ironwood Pharmaceuticals, Inc.: 1st of 4 in 2016Ironwood Pharmaceuticals, Inc.: 1st of 5 in 2017Ironwood Pharmaceuticals, Inc.: 1st of 5 in 2018Ironwood Pharmaceuticals, Inc.: 1st of 6 in 2019Ironwood Pharmaceuticals, Inc.: 1st of 7 in 2020Ironwood Pharmaceuticals, Inc.: 2nd of 8 in 2021Ironwood Pharmaceuticals, Inc.: 3rd of 8 in 2022Ironwood Pharmaceuticals, Inc.: 3rd of 7 in 2023Ironwood Pharmaceuticals, Inc.: 3rd of 7 in 2024Ironwood Pharmaceuticals, Inc.: 4th of 7 in 2025Ironwood Pharmaceuticals, Aquestive Therapeutics, Inc.: 3rd of 5 in 2017Aquestive Therapeutics, Inc.: 4th of 5 in 2018Aquestive Therapeutics, Inc.: 4th of 6 in 2019Aquestive Therapeutics, Inc.: 6th of 7 in 2020Aquestive Therapeutics, Inc.: 6th of 8 in 2021Aquestive Therapeutics, Inc.: 6th of 8 in 2022Aquestive Therapeutics, Inc.: 6th of 7 in 2023Aquestive Therapeutics, Inc.: 6th of 7 in 2024Aquestive Therapeutics, Inc.: 6th of 7 in 2025Aquestive Therapeutics, InEvolus, Inc.: 6th of 6 in 2019Evolus, Inc.: 4th of 7 in 2020Evolus, Inc.: 4th of 8 in 2021Evolus, Inc.: 4th of 8 in 2022Evolus, Inc.: 4th of 7 in 2023Evolus, Inc.: 4th of 7 in 2024Evolus, Inc.: 3rd of 7 in 2025Evolus, Inc.Alpha Teknova, Inc.: 7th of 7 in 2020Alpha Teknova, Inc.: 7th of 8 in 2021Alpha Teknova, Inc.: 7th of 8 in 2022Alpha Teknova, Inc.: 7th of 7 in 2023Alpha Teknova, Inc.: 7th of 7 in 2024Alpha Teknova, Inc.: 7th of 7 in 2025Alpha Teknova, Inc.Harrow Health: 3rd of 3 in 2013Harrow Health: 3rd of 3 in 2014Harrow Health: 3rd of 3 in 2015Harrow Health: 3rd of 4 in 2016Harrow Health: 5th of 5 in 2017Harrow Health: 5th of 5 in 2018Harrow Health: 5th of 6 in 2019Harrow Health: 5th of 7 in 2020Harrow Health: 5th of 8 in 2021Harrow Health: 5th of 8 in 2022Harrow Health: 5th of 7 in 2023Harrow Health: 5th of 7 in 2024Harrow Health: 5th of 7 in 2025Harrow HealthAmphastar Pharmaceuticals, Inc.: 1st of 2 in 2012Amphastar Pharmaceuticals, Inc.: 1st of 3 in 2013Amphastar Pharmaceuticals, Inc.: 1st of 3 in 2014Amphastar Pharmaceuticals, Inc.: 1st of 3 in 2015Amphastar Pharmaceuticals, Inc.: 2nd of 4 in 2016Amphastar Pharmaceuticals, Inc.: 2nd of 5 in 2017Amphastar Pharmaceuticals, Inc.: 2nd of 5 in 2018Amphastar Pharmaceuticals, Inc.: 2nd of 6 in 2019Amphastar Pharmaceuticals, Inc.: 2nd of 7 in 2020Amphastar Pharmaceuticals, Inc.: 1st of 8 in 2021Amphastar Pharmaceuticals, Inc.: 1st of 8 in 2022Amphastar Pharmaceuticals, Inc.: 1st of 7 in 2023Amphastar Pharmaceuticals, Inc.: 1st of 7 in 2024Amphastar Pharmaceuticals, Inc.: 2nd of 7 in 2025Amphastar Pharmaceuticals,
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearSolid Biosciences Inc.Collegium Pharmaceutical, Inc.Ironwood Pharmaceuticals, Inc.Aquestive Therapeutics, Inc.Evolus, Inc.Alpha Teknova, Inc.Harrow HealthAmphastar Pharmaceuticals, Inc.
2025—$781 MSEC1st$296 MSEC4th$45 MSEC6th$297 MSEC3rd$41 MSEC7th$272 MSEC5th$720 MSEC2nd
2024—$631 MSEC2nd$351 MSEC3rd$58 MSEC6th$266 MSEC4th$38 MSEC7th$200 MSEC5th$732 MSEC1st
2023—$567 MSEC2nd$443 MSEC3rd$51 MSEC6th$202 MSEC4th$37 MSEC7th$130 MSEC5th$644 MSEC1st
2022$8 MSEC8th$464 MSEC2nd$411 MSEC3rd$48 MSEC6th$149 MSEC4th$41 MSEC7th$89 MSEC5th$499 MSEC1st
2021$14 MSEC8th$277 MSEC3rd$414 MSEC2nd$51 MSEC6th$100 MSEC4th$37 MSEC7th$72 MSEC5th$438 MSEC1st
2020—$310 MSEC3rd$390 MSEC1st$46 MSEC6th$57 MSEC4th$31 MSEC7th$49 MSEC5th$350 MSEC2nd
2019—$297 MSEC3rd$428 MSEC1st$53 MSEC4th$35 MSEC6th—$51 MSEC5th$322 MSEC2nd
2018—$280 MSEC3rd$347 MSEC1st$67 MSEC4th——$41 MSEC5th$295 MSEC2nd
2017—$28 MSEC4th$298 MSEC1st$67 MSEC3rd——$27 MSEC5th$240 MSEC2nd
2016—$2 MSEC4th$274 MSEC1st———$20 MSEC3rd$255 MSEC2nd
2015——$150 MSEC2nd———$10 MSEC3rd$252 MSEC1st
2014——$76 MSEC2nd———$2 MSEC3rd$210 MSEC1st

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Solid Biosciences Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Collegium Pharmaceutical, Inc.COLL · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $715 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $715 M (Oct 28, 2026) · revenue $781 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Ironwood Pharmaceuticals, Inc.IRWD · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $599 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $599 M (Oct 30, 2026) · revenue $296 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    In the group
  • Aquestive Therapeutics, Inc.AQST · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $508 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $508 M (Oct 30, 2026) · revenue $45 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Evolus, Inc.EOLS · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $501 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $501 M (Oct 16, 2026) · revenue $297 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Alpha Teknova, Inc.TKNO · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $494 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $494 M (Oct 29, 2026) · revenue $41 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Harrow HealthHROW · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $1.1 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.1 B (Oct 28, 2026) · revenue $272 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Amphastar Pharmaceuticals, Inc.AMPH · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $1.1 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.1 B (Oct 28, 2026) · revenue $720 M (year to December 2025)
    97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)
    In the group
  • Emergent BioSolutions Inc.EBS · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $365 M market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $365 M (Oct 29, 2026) · revenue $743 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    + Add
  • Pacira BioSciences, Inc.PCRX · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $1.5 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.5 B (Oct 29, 2026) · revenue $726 M (year to December 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • Phibro Animal Health CorporationPAHC · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $1.6 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.6 B (Oct 30, 2026) · revenue $1.5 B (year to June 2026)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • ANI Pharmaceuticals, Inc.ANIP · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $1.6 B market cap against $713 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $1.6 B (Oct 9, 2026) · revenue $883 M (year to December 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • Bayport International Holdings Inc.BAYP · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $820 M market cap against $713 M · Same country: USA
    Market cap $820 M (last known, Jan 7, 2022)
    94 of 100 (industry or sector 50 + size 29 + country 15)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.